Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 Ocular adverse events over a 6-month period from pegaptanib treatment initiation.

From: Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study

Adverse event Number of subjects with occurrence Total number of occurrences Rate of occurrence by number of injections*
Endophthalmitis 1 1 0.003
Retinal detachment 0 0 0
Increased intraocular pressure 0 0 0
Retinal tear 0 0 0
Traumatic cataract 0 0 0
Vitreous haemorrhage 0 0 0
Geographic atrophy 2 2 0.006
Other 0 0 0
  1. * Based on 326 total injections received by study subjects.
  2. Unclear history.